Abstract:ObjectiveTo investigate the changes of natural killer-like B (NKB) cells, natural killer (NK) cells, and B cells and their correlation with clinical indices in patients with hepatitis B virus (HBV) infection. MethodsA total of 15 patients with acute hepatitis B (AHB), 30 patients with chronic hepatitis B (CHB), 29 asymptomatic HBV carriers (ASCs), and 12 controls who attended Tangdu Hospital from January 2017 and December 2018 were enrolled. Peripheral blood samples were collected, and plasma and peripheral blood mononuclear cells (PBMCs) were isolated. ELISA was used to measure the plasma levels of interleukin-18 (IL-18) and interferon-γ (IFNγ), and enzyme-linked immunospot assay was used to measure the level of IFNγ secreted by HBV-specific CD8+ T cells; flow cytometry was used to measure the percentages of CD3-CD19+CD56+CD16+ NKB cells, different NK cell subsets (including CD3-CD19-CD56highCD16- NK cells, CD3-CD19-CD56+CD16+ NK cells, and CD3-CD19-CD56-CD16+ NK cells), and their correlation with viral replication and liver inflammation markers was analyzed. A one-way analysis of variance was used for comparison of normally distributed continuous data between multiple groups, and the least significant difference t-test was used for further comparison between two groups; non-normally distributed continuous data were expressed as M(P25-P75), and the Kruskal-Wallis H test was used for comparison between multiple groups; the Pearson correlation test was used for correlation analysis. ResultsThere was a significant difference in the percentage of CD3-CD19+CD16+CD56+ NKB cells between the AHB patients, CHB patients, ASCs, and controls (F = 16.42, P ＜0.000 1), and the CHB patients had a significantly lower percentage of NKB cells than the AHB patients, ASCs, and controls (0.79%±0.13% vs 0.94%±0.15%/1.02%±0.12%/1.11%±0.27%, all P ＜0.001). There was a significant difference in plasma IL-18 level between the AHB patients, CHB patients, ASCs, and controls (F = 5.733, P = 0.001); the CHB patients had a significantly lower IL-18 level than the AHB patients and the controls (259.30±70.09 pg/mL vs 336.00±103.00 pg/mL and 319.30±64.80 pg/mL, both P ＜0.05), and ASCs had a significantly lower IL-18 level (258.60±59.82 pg/mL) than the AHB patients and the controls (both P ＜0.01), while there was no significant difference in plasma IL-18 level between the CHB patients and ASCs (P = 0.965). There were no significant differences in the percentage of CD3-CD19-CD56highCD16- NK cells, CD3-CD19-CD56+CD16+ NK cells, CD3-CD19-CD56-CD16+ NK cells, and B cells between the four groups (all P ＞0.05). The CHB patients had a significantly lower plasma IFNγ level than the AHB patients, ASCs, and controls (all P ＜0.01). The percentage of NKB cells and the level of IL-18 were not significantly correlated with HBV DNA quantification or alanine aminotransferase level (all P ＞0.05). In the CHB patients, the percentage of NKB cells was positively correlated with plasma IL-18 level (r = 0.432, P = 0.017) and the level of IFNγ secreted by HBV-specific CD8+ T cells (r =0493, P=0.006). ConclusionNKB cells and IL-18 might be involved in the chronicity of HBV infection and is associated with the natural history of chronic HBV infection.

The impact of hepatitis B surface antigen on natural killer cells in patients with chronic hepatitis B virus infection

Analysis on Clinical Features and Immunity in Chronic Hepatitis B Virus Infected Patients with Low-Level Hbsag

Immune Checkpoint Molecules Expressed on CD4+ T Cell Subsets in Chronic Asymptomatic Hepatitis B Virus Carriers with Hepatitis B E Antigen-Negative

Hepatitis B surface antigen levels during natural history of chronic hepatitis B: a Chinese perspective study.

Effects of Hepatitis B Surface Antigen on Virus-Specific and Global T Cells in Patients with Chronic Hepatitis B Virus Infection

HBsAg Levels in HBeAg-positive Chronic Hepatitis B Patients with Different Immune Conditions.

Recovery of Circulating CD56dim NK Cells and the Balance of Th17/Treg after Nucleoside Analog Therapy in Patients with Chronic Hepatitis B and Low Levels of HBsAg

Peripheral NK cell phenotypic alteration and dysfunctional state post hepatitis B subviral particles stimulation in CHB patients: evading immune surveillance

Changes and Clinical Significance of Natural Killer-Like B Cells, Natural Killer Cells, and B Cells in Peripheral Blood of Patients with Hepatitis B Virus Infection

Hepatitis B e Antigen Induces NKG2A+ Natural Killer Cell Dysfunction via Regulatory T Cell-Derived Interleukin 10 in Chronic Hepatitis B Virus Infection

Hepatitis B Virus Antigens Impair NK Cell Function

Altered Immune Profiles Of Natural Killer Cells In Chronic Hepatitis B Patients: A Systematic Review And Meta-Analysis

HBsAg Stimulates NKG2D Receptor Expression on Natural Killer Cells and Inhibits Hepatitis C Virus Replication

Expressions of natural killer-associated receptors on cytotoxic T lymphocyte from peripheral blood of patients with chronic hepatitis B

Decreased Peripheral Natural Killer Cells Activity In The Immune Activated Stage Of Chronic Hepatitis B

ADCC-Mediated CD56dim NK Cell Responses Are Associated with Early HBsAg Clearance in Acute HBV Infection

Functional molecular expression of nature killer cells correlated to HBsAg clearance in HBeAg-positive chronic hepatitis B patients during PEG-IFN α-2a therapy

Hepatitis B surface antigen reduction is associated with hepatitis B core-specific CD8+ T cell quality

Recovery of host adaptive immune function promoted the reduction of hepatitis B surface antigen in nucleoside analog-experienced chronic hepatitis B patients with low hepatitis B surface antigen levels

Hepatitis B virus suppresses the functional interaction between natural killer cells and plasmacytoid dendritic cells.

Natural Killer Cells Are Characterized by the Concomitantly Increased Interferon-γ and Cytotoxicity in Acute Resolved Hepatitis B Patients